A study sponsored by Takeda Pharmaceutical has found that its experimental diabetes drug was more effective than older generic medicine in lowering blood sugar with fewer side effects.
Around 426 patients with type 2 diabetes took part in the study which tested the effectiveness of Takeda's TAK 875 drug in lowering blood sugar. The study was conducted by researchers from University of Michigan who gave five different doses (6.25 mg, 25 mg, 50 mg, 100 mg, and 200 mg) of TAK 875 to 303 patients while the remaining participants received glimepiride.
The researchers found that patients who received TAK 875 dosage of 25 mg and above managed to reduce their blood sugar levels by 48 percent within 12 weeks compared to just 40 percent among those who took glimepiride.
Writing in their report, published in The Lancet, the researchers said, "We are truly excited about the potential of TAK-875 and are eager to conduct larger trials to find out how well this drug works, how safe it is and what its place is in the treatment of diabetes."